(KRYS) Krystal Biotech - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 8.873m USD | Total Return: 126% in 12m
Avg Turnover: 75.5M
Qual. Beats: 0
Rev. Trend: 92.5%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Rs Leader, Idiosyncratic Leader, Tailwind, Confidence
Krystal Biotech, Inc. (KRYS) is a commercial-stage biotechnology firm specializing in the development and manufacturing of redosable gene therapies. The company utilizes its proprietary Skin TARgeted Delivery (STAR-D) platform, based on an engineered viral vector, to deliver functional genes directly to patient cells. Its lead product, VYJUVEK, is the first FDA-approved redosable gene therapy for dystrophic epidermolysis bullosa (DEB).
The company maintains a diverse clinical pipeline targeting respiratory, ophthalmic, and oncological indications, including active Phase 1 and Phase 2 trials for cystic fibrosis and solid tumors. Unlike traditional gene therapies that often require one-time high-dose administration, Krystals platform is designed for repeatable dosing to manage chronic genetic conditions. This vertically integrated business model includes in-house manufacturing facilities to control the production of its viral vectors.
The biotechnology sector often faces high volatility due to clinical trial outcomes and regulatory milestones. Examining the valuation metrics on ValueRay can provide further context on the companys market position. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania, and continues to expand its genetic medicine portfolio into aesthetic and rare disease markets.
- VYJUVEK commercial uptake and patient conversion rates drive immediate revenue growth
- Pipeline expansion into cystic fibrosis and solid tumors mitigates single-asset risk
- Regulatory approval timelines for ophthalmic B-VEC influence near-term valuation
- In-house manufacturing scaling efficiency impacts long-term operating margins and profitability
- Expansion of the STAR-D platform into aesthetic dermatology diversifies market exposure
| Net Income: 225.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.17 > 0.02 and ΔFCF/TA 4.96 > 1.0 |
| NWC/Revenue: 218.5% < 20% (prev 206.1%; Δ 12.41% < -1%) |
| CFO/TA 0.18 > 3% & CFO 250.3m > Net Income 225.0m |
| Net Debt (-812.5m) to EBITDA (185.4m): -4.38 < 3 |
| Current Ratio: 9.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (30.5m) vs 12m ago 2.13% < -2% |
| Gross Margin: 92.79% > 18% (prev 93.20%; Δ -0.41% > 0.5%) |
| Asset Turnover: 33.77% > 50% (prev 31.04%; Δ 2.74% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.65 (Total Current Assets 1.02b - Total Current Liabilities 107.8m) / Total Assets 1.40b |
| B: 0.06 (Retained Earnings 80.1m / Total Assets 1.40b) |
| C: 0.14 (EBIT TTM 178.8m / Avg Total Assets 1.24b) |
| D: 10.62 (Book Value of Equity 1.28b / Total Liabilities 120.2m) |
| Altman-Z'' = 16.59 = AAA |
| DSRI: 0.98 (Receivables 127.0m/103.3m, Revenue 417.3m/333.4m) |
| GMI: 1.00 (GM 93.20% / 92.79%) |
| AQI: 1.12 (AQ_t 0.16 / AQ_t-1 0.14) |
| SGI: 1.25 (Revenue 417.3m / 333.4m) |
| TATA: -0.02 (NI 225.0m - CFO 250.3m) / TA 1.40b) |
| Beneish M = -2.79 (Cap -4..+1) = A |
As of June 11, 2026, the stock is trading at USD 312.41 with a total of 291,572 shares traded.
Over the past week, the price has changed by +3.51%,
over one month by -0.15%,
over three months by +19.66% and
over the past year by +126.04%.
Krystal Biotech has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy KRYS.
- StrongBuy: 8
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 322.8 | 3.3% |
P/E Trailing = 40.1869
P/E Forward = 43.6681
P/S = 21.9567
P/B = 6.8831
Revenue TTM = 417.3m USD
EBIT TTM = 178.8m USD
EBITDA TTM = 185.4m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 1.80m USD (from shortTermDebt, last quarter)
Debt = 10.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 9.11m
Net Debt = -812.5m USD (calculated: Debt 10.9m - CCE 823.4m)
Enterprise Value = 8.06b USD (8.87b + Debt 10.9m - CCE 823.4m)
Interest Coverage Ratio = unknown (Ebit TTM 178.8m / Interest Expense TTM 0.0)
EV/FCF = 33.96x (Enterprise Value 8.06b / FCF TTM 237.4m)
FCF Yield = 2.94% (FCF TTM 237.4m / Enterprise Value 8.06b)
FCF Margin = 56.88% (FCF TTM 237.4m / Revenue TTM 417.3m)
Net Margin = 53.92% (Net Income TTM 225.0m / Revenue TTM 417.3m)
Gross Margin = 92.79% ((Revenue TTM 417.3m - Cost of Revenue TTM 30.1m) / Revenue TTM)
Gross Margin QoQ = 94.57% (prev 89.81%)
Tobins Q-Ratio = 5.77 (Enterprise Value 8.06b / Total Assets 1.40b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 10.9m)
Taxrate = 8.97% (5.51m / 61.4m)
NOPAT = 162.8m (EBIT 178.8m * (1 - 8.97%))
Current Ratio = 9.46 (Total Current Assets 1.02b / Total Current Liabilities 107.8m)
Debt / Equity = 0.01 (Debt 10.9m / totalStockholderEquity, last quarter 1.28b)
Debt / EBITDA = -4.38 (Net Debt -812.5m / EBITDA 185.4m)
Debt / FCF = -3.42 (Net Debt -812.5m / FCF TTM 237.4m)
Total Stockholder Equity = 1.17b (last 4 quarters mean from totalStockholderEquity)
RoA = 18.21% (Net Income 225.0m / Total Assets 1.40b)
RoE = 19.25% (Net Income TTM 225.0m / Total Stockholder Equity 1.17b)
RoCE = 15.30% (EBIT 178.8m / Capital Employed (Equity 1.17b + L.T.Debt 0.0))
RoIC = 12.82% (NOPAT 162.8m / Invested Capital 1.27b)
WACC = 10.02% (E(8.87b)/V(8.88b) * Re(10.03%) + D(10.9m)/V(8.88b) * Rd(0.0%) * (1-Tc(0.09)))
Discount Rate = 10.03% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 60.0 | Cagr: 2.56%
[DCF] Terminal Value 72.77% ; FCFF base≈194.2m ; Y1≈222.6m ; Y5≈327.6m
[DCF] Fair Price = 156.7 (EV 3.81b - Net Debt -812.5m = Equity 4.62b / Shares 29.5m; r=10.02% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.68 | # QB: 0
Revenue Correlation: 92.47 | Revenue CAGR: 177.0% | SUE: 0.99 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.94 | Chg30d=+15.23% | Revisions=-14% | Analysts=9
EPS next Quarter (2026-09-30): EPS=2.19 | Chg30d=+10.32% | Revisions=-25% | Analysts=9
EPS current Year (2026-12-31): EPS=8.38 | Chg30d=+10.59% | Revisions=+11% | GrowthEPS=+22.5% | GrowthRev=+35.9%
EPS next Year (2027-12-31): EPS=10.08 | Chg30d=-1.13% | Revisions=+20% | GrowthEPS=+20.3% | GrowthRev=+28.1%
[Analyst] Revisions Ratio: -25%